1504 studies found for:    EGFR
Show Display Options
Rank Status Study
21 Recruiting INHERIT EGFR - Studying Germline EGFR Mutations
Condition: Lung Cancer
22 Active, not recruiting A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).
Condition: Non Small Cell Lung Cancer
23 Not yet recruiting C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).
Conditions: Lung Cancer;   Pancreatic Cancer
Intervention: Other: C11-Erlotinib PET/CT
24 Completed Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
25 Completed Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients
Condition: Solid Tumor
Interventions: Drug: enzyme inhibitor therapy;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
26 Recruiting Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
27 Recruiting Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Squamous Cell Carcinoma;   Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
28 Active, not recruiting Detecting EGFR T790M Mutations From Circulating Tumor Cells
Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
29 Completed Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Condition: Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
30 Recruiting Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
Condition: Stage IV Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Fulvestrant;   Drug: Erlotinib
31 Recruiting A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
Condition: EGFR Positive Solid Tumors
Intervention: Drug: IMGN289
32 Not yet recruiting Safety and Efficacy Study of CO-1686 or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: CO-1686 Mono-Therapy;   Drug: Erlotinib Mono-Therapy
33 Completed Retrospective Study in a NSCLC M+ p
Condition: EGFR Mutated Non-small Cell Lung Cancer Patients
34 Recruiting A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in Non-small Cell Lung Cancer(NSCLC)Treatment
Conditions: Non-small Cell Lung Cancer (NSCLC);;   EGFR-TKI Resistant Mutation;;   EGFR-TKI Sensitizing Mutation;;   Germline Mutations
35 Not yet recruiting Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Condition: EGFR Mutation Positive Non Small Cell Lung Cancer
36 Recruiting Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Positive EGFR Mutation
Intervention: Drug: BIBW 2992
37 Active, not recruiting Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
38 Recruiting Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
Condition: Non Small Cell Lung Cancer
Interventions: Drug: combined group;   Drug: Sequenced group
39 Recruiting Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor
Condition: Non-Small-Cell Lung Cancer
40 Terminated
Has Results
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Tarceva

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years